All-Cause, Stroke/Systemic Embolism-, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants.

Clin Appl Thromb Hemost · 2018 · PMC6714709 · PMID 29363999

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Stroke/SE-related medical costs (US$32 vs US$15 PPPM, P = .19; Figure 4 ) and MB-related medical costs (US$81 vs US$45 PPPM, P = .11; Figure 5 ) were numerically higher for patients treated with dabigatran compared to those treated with apixaban, but the differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.